Antiaging compounds: (-)Deprenyl (selegiline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Hundreds of millions of people now die over the age of 80 years primarily due to twentieth century progress in hygiene, chemotherapy, and immunology. With a longer average lifespan, the need to improve quality of life during the latter decades is more compelling. "Aging - The Epidemic of the New Millenium," a recent international conference (Monte Carlo, June 17-18, 2000), showed with peculiar clarity that a safe and efficient drug strategy to slow the age-related decay of brain performance is still missing. This review summarizes the physiologic and pharmacologic arguments in favor of a peculiar lifelong prophylactic medication with reasonable chances to keep in check brain aging and decrease the precipitation of age-related neurological diseases.

Original languageEnglish
Pages (from-to)317-345
Number of pages29
JournalCNS Drug Reviews
Volume7
Issue number3
Publication statusPublished - Dec 1 2001

Keywords

  • Antiaging drugs
  • BPAP
  • Deprenyl
  • Selegiline

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Pharmacology

Fingerprint Dive into the research topics of 'Antiaging compounds: (-)Deprenyl (selegiline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain'. Together they form a unique fingerprint.

  • Cite this